Combined immunotherapy and radiotherapy in metastatic bladder cancer
10.3760/cma.j.cn112330-20221202-00642
- VernacularTitle:免疫治疗联合放疗用于转移性膀胱癌的研究进展
- Author:
Jun DU
1
;
Guowei FENG
;
Xin YAO
Author Information
1. 天津医科大学肿瘤医院泌尿肿瘤科 国家恶性肿瘤临床医学研究中心 天津市恶性肿瘤临床医学研究中心 天津市肿瘤防治重点实验室，天津 300060
- Keywords:
Urinary bladder neoplasms;
Urothelial cancer;
Immunotherapy;
Immune checkpoint inhibitor;
Radiotherapy;
Stereotactic body radiotherapy
- From:
Chinese Journal of Urology
2024;45(6):481-484
- CountryChina
- Language:Chinese
-
Abstract:
Immune checkpoint inhibitors have cahnged the management of patients with metastatic bladder cancer, by leading to long-term response and prolonged survival in a subset of patients. Unfortunately, only one in five patients with metastatic bladder cancer responds to immune checkpoint inhibitors. Preclinical and early clinical evidence indicates that radiotherapy not only acts locally, but It also plays a "double-edged sword" role in the immune system. It is hypothesized that combining checkpoint inhibitors with radiotherapy might enhance an anti-tumor immune response and increase response rates. With a review of research progresses in recent years, we believe that immunotherapy combined with radiotherapy may have a good applied perspective and is expected to further change the treatment pattern of metastatic bladder cancer.
